Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
singIST: An integrative method for comparative single-cell transcriptomics between disease models and humans.
PMID 41838773 · PMC13008255 · PLoS computational biology · 2026 · 8 claims · 7 setups
singIST provides explainable quantitative measures of disease model similarity to a human reference at the pathway, cell type, and gene levels
-
Full-text index only
Distinct phenotypes and repertoires of bronchoalveolar and airway mucosal T cells in health and allergic asthma.
PMID 41519381 · PMC12983186 · Mucosal immunology · 2026 · 8 claims · 6 setups
BAL and endobronchial brush sampling capture phenotypically and clonally distinct T cell populations
-
Full-text index only
Matcha alleviates sneezing response in a murine model of allergic rhinitis.
PMID 41786771 · PMC13022397 · NPJ science of food · 2026 · 8 claims · 8 setups
Matcha suppresses allergen-induced immediate nasal response (INR) and nasal hyperresponsiveness (NHR) in an OVA-immunized mouse model
-
Full-text index only
Development of a pediatric immune cell atlas and characterization of CD4+ T cells in food allergy.
PMID 42025535 · PMC13105851 · Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026 · 8 claims · 8 setups
A pediatric single-cell PBMC reference atlas was developed from 57 healthy children across 8 public scRNA-seq studies.
-
Has reproduction · 75
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.
PMID 33188038 · PMC7668369 · Journal for immunotherapy of cancer · 2020 · 7 claims · 6 setups
The frequency of circulating PD-1+TIGIT+ (DPOS) CD8+ T cells after 1 month of anti-PD-1 therapy is associated with clinical response and overall survival